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1.0 Introduction 
1.1 Circadian Rhythms and the 
Suprachiasmatic Nucleus 
 
 Circadian clocks regulate 
physiological processes in nearly all 
organisms. Located within the 
hypothalamus, the mammalian central 
clock identified as the suprachiasmatic 
nucleus (SCN) synchronizes peripheral 
clocks. Lesioning the SCN eliminates 
circadian rhythm patterns associated 
with body temperature, sleep, locomotor 
activity and hormones [1-3]. Retinal 
ganglion cells signal the presence of light 
to the SCN via the retinohypothalamic 
tract (RHT) and release of the 
neurotransmitter, glutamate. The 
intracellular processes associated with 
glutamate signaling (outlined below) are 
well understood; however, the 
extracellular processes involved with 
light-induced glutamate signaling are not 
completely understood.  
 
The focus of my research is on a 
group of extracellular proteins best 
known for their role in the vasculature to 
regulate fibrinolysis: tissue-type 
plasminogen activator (tPA), 
plasminogen, and plasminogen activator 
inhibitor-1 (PAI-1). Experiments have 
determined that these proteins also 
function in SCN to modulate photic 
regulation of the circadian clock. Brain-
derived neurotrophic factor (BDNF) is 
required for light/glutamate to reset the 
clock; it is activated by plasmin which is 
produced from plasminogen by tPA [4]. 
Glutamate-induced phase shifts are 
blocked by PAI-1, which stays active 
through binding with vitronectin, (VN) 
[4]. However, the precise spatial and 
temporal characteristics of these proteins’ 
activities and interactions have yet to be 
determined. Our goal is to answer 
questions about the mechanisms through 
which these proteins regulate glutamate 
signaling in the SCN. This includes spatial 
location of tPA and PAI-1 in the SCN and 
how they change over the circadian cycle. 
 
1.2 Importance of Fibrinolytic 
Proteins in Clinical Areas 
The roles of tPA, PAI-1 and 
plasminogen in fibrinolysis are well 
known. Fibrinolysis, the body’s ability to 
degrade fibrin, is an integrated part of 
hemostasis. Overactivity causes bleeding 
and underactivity causes thrombosis. 
Abnormal structural variants and 
abnormal levels of tPA, PAI-1 and 
plasminogen give rise to bleeding or to 
thrombosis [5]. The biological control of 
tPA-mediated fibrinolysis is both cellular 
and humoral, indicating its physiological 
importance [6]. The cellular regulation 
involves synthesis of tPA and PAI-1 as 
well as their release/uptake. The humoral 
regulation includes the tPA/PAI-1 
reaction, the fibrin-stimulated 
plasminogen activation and the plasmin 
degradation of fibrin [6]. More recently 
these proteins have been shown to affect 
normal brain functions, including neural 
remodeling in early development, stress-
induced anxiety in the amygdala, and 
learning behaviors [7-10]. tPA’s activity in 
the brain is most prominent in the 
hippocampus and the hypothalamus[11]. 
However, less is known about the roles 
these extracellular proteases play in the 
SCN. 
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1.3 Tissue-type Plasminogen 
Activator (tPA) & Plasmin 
Tissue-type plasminogen activator 
(tPA) is an extracellular protease that 
cleaves plasminogen into the active form 
plasmin. This is a crucial step in the 
cascade of events shown in Figure 1. In 
the vasculature this helps regulate 
fibrinolysis, while in the brain it appears 
to regulate NMDA/glutamate signaling 
(12, 13).  There is accumulating evidence 
that tPA/plasmin are involved in SCN 
physiology. 
 
The SCN is anatomically and 
functionally organized into two 
subdivisions: a core that lies adjacent to 
the optic chiasm and a shell that 
surrounds the core in its dorsomedial 
portion [14]. Plasminogen expression is 
prominent in the dorsomedial shell 
portion of the SCN [14]. tPA has been 
shown to localize at vasopressin-
containing neurons within the SCN, where 
high levels of plasminogen have been 
found [15, 16]. Due to the actions of tPA 
on plasminogen, it is expected to be 
located in the same region of the brain as 
plasminogen. tPA is often found in 
extracellular milieu, as a soluble protein, 
or bound to extracellular matrix (ECM) or 
cell-surface receptors; its activity 
depends on its location and partners with 
which it interacts. For example, tPA can 
bind to the ECM proteins fibrin [17, 18] 
and laminin [19, 20] or to annexin II [21-
23] and α-enolase [23, 24]located on cell 
membranes. tPA is inhibited directly or 
indirectly by several proteins but we will 
focus on its inhibition by plasminogen 
activator inhibitor (PAI-1); PAI-1 stability 
is enhanced when it is bound to 
vitronection (VN) as described in Section 
1.4. It has been determined that tPA 
mRNA levels are expressed rhythmically 
in the adult SCN, with a peak in late day 
[25]. 
 
As mentioned, the product of tPA 
cleavage of plasminogen is plasmin. 
Plasmin has well documented roles in 
fibrinolysis [26], wound healing [27], and 
ECM degradation [27]. In the 
hippocampus, plasmin converts the 
inactive pro-BDNF to the active form, 
mBDNF, which is necessary to enhance 
the cellular processes associated with 
long term potentiation (LTP), which 
underlies learning [20]. Our research 
suggests that tPA and plasmin function in 
a similar manner in the SCN. α2-
antiplasmin (an endogenous inhibitor of 
plasmin) inhibits glutamate-induced 
phase shifts and decreases the conversion 
of inactive to active BDNF in the SCN [4]. 
Exogenous mBDNF (200 ng/mL) applied 
30 minutes prior to co-application of 
glutamate and α2-antiplasmin fully 
restores the glutamate-induced phase 
shifts [4]. This phase shift cannot be 
accomplished without the presence of 
glutamate; mBDNF on its own has no 
effect on the phase shift [4]. These data 
support the model shown in Figure 1; our 
working model is that plasmin cleaves the 
inactive form of BDNF, pro-BDNF, into the 
active form, m-BDNF. m-BDNF activates 
the TrkB receptor, which in turn 
enhances NMDA channel activity. This 
ultimately allows glutamate to induce 
clock phase shifts. 
1.4 Plasminogen Activator 
Inhibitor-1 (PAI-1) & Vitronectin 
 
PAI-1 is a protease that acts 
primarily to inhibit tPA activity. PAI-1 
binds to a glycoprotein called vitronectin 
(VN); this interaction increases PAI-1’s 
stability 10-fold. Similar to tPA, PAI-1 
mRNA levels are expressed rhythmically 
McClintock Honors Thesis     Prosser Lab Spring 2011 
5 
 
in the adult SCN. PAI-1 mRNA levels peak 
approximately 6 hours after peak levels of 
tPA mRNA [28]; PAI-1 mRNA levels are 
modulated by BDNF [29]. In previous 
studies, PAI-1 effects in the SCN were well 
documented. Glutamate (1mM) applied to 
brain slices in the early subjective night 
for 10 minutes delayed the SCN neuronal 
activity rhythm by 2-3 hours [4]. 
Pretreating the brain slices with PAI-1 for 
30 minutes prior to glutamate application 
blocked these glutamate-induced phase-
shifts from occurring [4]. This inhibition 
is dependent on PAI-1 dosage and can be 
overcome by excess tPA application [4].  
  
VN (62 kD glycoprotein) stabilizes 
PAI-1 by opposing PAI-1’s tendency to 
relax to an inactive form [30-33]. It is 
necessary for PAI-1 actions in the SCN[4]. 
Experiments have shown that PAI-1 is not 
capable of blocking glutamate-induced 
phase shifts in brain slices prepared from 
VN knockout mice; PAI-1 could not inhibit 
these phase shifts without its cofactor, VN 
[4].  VN stabilizes PAI-1 via extensive 
interactions and also localizes PAI-1 to 
specific extracellular locations. Notably, 
VN is expressed in neural tissues during 
development and following trauma [34-
40]. Microarray studies have found that 
VN mRNA is expressed in the SCN but is 
not rhythmic [41]. 
1.5 Proposal & Hypothesis 
 We believe that the fibrinolytic 
proteins described above affect the 
circadian clock in part through their 
ability to activate BDNF. If this is the case, 
then these proteins should be localized 
extracellularly, possibly associated with 
the extracellular matrix. Our goal is to 
assess the spatial location of the above 
mentioned proteins and how they change 
over the circadian cycle. SCN2.2 cells are a 
good model system in which to study 
these proteins. This is an immortalized 
cell line derived from rat SCN. Its 
distinguishing characteristic is the ability 
to generate circadian rhythms similar to 
those of the SCN in vivo [42]. Thus, these 
cells are not only capable of measuring 
time (like a clock) but also of regulating 
the timing of other events (as a 
pacemaker). Their pace-making ability 
has been determined in vivo. The 
behavioral activity of intact rats is highest 
at night, while SCN-lesioned rats exhibit 
arrhythmicity. After transplantation of 
SCN2.2 cells into the hypothalamus, the 
circadian rhythm of wheel-running 
behavior was restored within 4-10 days 
[42]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glutamate 
Flows in NMDA Glutamate 
Channel 
Opens 
m-BDNF 
(active) 
Pro-BDNF 
(inactive) 
Plasmin 
Plasminogen 
tPA 
CLOCK SHIFT! 
TrkB  
Receptor 
Interacts 
with 
receptor 
PAI-1 
VN INHIBITS 
Figure 1. The extracellular protease, tPA, cleaves 
plasminogen into plasmin. Plasmin turns the inactive form 
of BDNF, pro-BDNF, into the active form, m-BDNF. m-BDNF 
interacts with the TrkB Receptor on the cell membrane, 
opening up the glutamate NMDA channels. Glutamate now 
freely flows in the cell and causes a clock shift. As shown, 
tPA activity is inhibited by the PAI-1/VN complex. 
McClintock Honors Thesis     Prosser Lab Spring 2011 
6 
 
2.0 Methods 
2.1 Cell Culture Procedure 
 
Frozen, immortalized SCN 2.2 cells 
were thawed out and grown in laminin-
coated flasks at 37°C in Minimal Essential 
Media (Gibco) supplemented with 10% 
FBS (Fetal Bovine Serum), 2% glucose, 
1% glutamine and 1% gentamicin until 
>60% confluence. Before cells were 
harvested, samples of media were 
collected and stored at -80°C. Following 
media collection, cells were rinsed with 6 
ml of DPBS (Dulbecco PBS). Cells were 
then lifted and lysed in 1 ml of 0.2M 
ammonium hydroxide after a ten minute 
incubation. Cell extracts were collected 
and immediately stored at -80°C.  
 
For time-course samples, prior to 
harvesting, cells were treated with 
forskolin (FSK) dissolved in dimethyl 
sulfoxide to synchronize the cells 
(denoted as circadian time 0) or with 
vehicle. Both FSK- or vehicle-treated 
samples were collected at 3 hour 
increments for up to 27 hours subsequent 
to treatment. 
 
2.2 Protein Extraction Procedure 
 
To assess protein expression, rat 
SCN2.2 cells were isolated into three 
fractions (media, ECM and cells) and then 
frozen at -80°C for later Western blot 
assay. These fractions were supplied by 
former lab postdoctoral, Dr. Beth 
Cantwell. 
 
Trichloroacetic acid (TCA) was 
used to precipitate proteins (from cell 
fractions).  Our protocol has been slightly 
modified from the classical TCA 
procedures in that we do not incubate our 
proteins on ice or at -20°C for any amount 
of time [43, 43].  The TCA/acetone 
protein extraction procedure was chosen 
to precipitate the proteins because it has 
been proven to produce highly purified 
tPA with a high yield [45]. After adding 
ten percent volume of ice-cold 100% TCA 
to each sample, samples were centrifuged 
at 4°C for 30 minutes at 17,000 RPM, and 
then the supernatant was discarded. 250 
µl of ice-cold 1% TCA in acetone was 
added to wash the pellet. Samples were 
then vortexed, centrifuged at 4°C for 15 
minutes at 17,000 RPM and the 
supernatant was removed. After washing 
twice with 1% TCA, the pellet was further 
washed with 250 µl of ice-cold acetone, 
centrifuged at 4°C for 5 minutes at 17,000 
RPM and the supernatant was removed. 
The samples were left to dry overnight. 
The pellets were resuspended in 
1X loading buffer containing sodium 
dodecyl sulfate (SDS) and dithiothreitol, 
followed by a series of boiling and mixing 
steps. Each boiling step was 5 minutes 
and at 100°C, and samples are stored in -
20°C or immediately used for western 
blotting. 
2.3 Western Blots 
SDS-Page and Immunoblotting 
 
TCA-extracted samples were 
boiled for 5 minutes and loaded into 10% 
SDS-polyacrylamide gels. Proteins in the 
samples were separated by size and 
transferred onto nitrocellulose by 
electrophoresis in Tris-Glycine buffer. 
Membranes were then rinsed with PBST 
(1X phosphate buffered saline with 0.05% 
Tween-20) and blocked in PBST with 
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10% milk. Primary antibodies were 
applied for 2 hours at room temperature 
or overnight at -4°C, rinsed, and 
incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies 
for 1 hour. The primary antibody used 
was rabbit-anti-mouse (Molecular 
Innovations) in a concentration of 1:1000 
with 2% milk and the secondary 
was horse-anti-mouse IgG (Vector 
Laboratories) in a concentration of 
1:2000 with 2% milk. Visualization was 
performed using Supersignal West Pico 
(Thermoscientific), a chemiluminescent 
substrate cleaved by HRP. 
 
3.0 Results 
Cell extracts and media prepared 
by TCA extraction were subjected to SDS
 
Vehicle-treated cell extract 
samples are shown alongside PAI
tPA positive controls in Figure 3. This 
immunoblot shows weak expression of 
tPA protein positive control. The 
positive control shows cross-reactivity
the rabbit polyclonal, anti-mouse tPA 
antibody. Later blots attempted to 
address these re-occurring issues. 
    Prosser Lab Spring 2011
antibody 
-
PAGE followed by western blotting with 
antibodies for tPA as shown in Figure 2. 
The tPA antibody gave immunoreactive 
bands at approximately 62 kD, 
corresponding to the expected wei
this point, our positive control (purified
PA protein) did not give a strong signal, 
but we later confirmed the band 
corresponded with the native protein. As 
shown in Figure 2, the cell extract 
replicates do not show up consistently. 
However, the media extracts have much 
higher levels of protein. 
 
Each band shown in Figures 2, 3,
and 5 lies at approximately 62
matched the positive control as shown in 
Figure 3 and Figure 5 and is con
with previous studies [4].
 
 
 
 
 
 
 
 
-1 and 
PAI-1 
 to 
In 
many of our cell extract 
including those in Figure 3, we attempted 
to blot for actin, which is a structural 
protein that should act to normalize the 
amount of target protein in order to 
control between groups.
were not successful as no reactivity
appeared even in the extended (20 
minutes) exposures. 
 
7 
ght. At 
 
 4 
-kD, which 
sistent 
 
experiments, 
 However, we 
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The vehicle treated cells act as a 
control for the forskolin treated cells. 
Forskolin activates adenylate cyclase [
and is known to synchronize SCN cells 
vitro [47]. Figure 4 shows two w
blots of time-course samples that had 
 
 While the cell extract samples 
shown in Figure 5 below are not showing 
a consistent amount of protein, the PAI
and tPA positive controls have a much 
    Prosser Lab Spring 2011
 
 
 
 
46] 
in 
estern 
 
 
been collected from circadian time (CT) 3 
to CT27. Figure 4A shows a vehicle
synchronized blot compared to Figure 
showing a forskolin-synchronized blot. In 
Figure 4B, expression at CT6 and CT9 
were particularly high.
-1 
stronger presence even when loading a 
small amount. This is due to using new 
stock products.
 
 
 
 
8 
 
-
4B 
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4.0 Discussion 
 
 The extracellular processes that 
regulate glutamate signaling in the SCN 
(and therefore its light-induced circadian 
activity) are largely unknown. From our 
previous study involving PAI-1/VN and 
the tPA/plasmin proteolytic cascade, the 
regulation of mBDNF production by these 
proteins is a critical factor for the SCN 
clock to respond to light/glutamate 
signaling [4]. Prior studies have shown 
that tPA is released into the extracellular 
space, shifting the balance of proBDNF 
secreted from dendrites to mature BDNF 
[48].  Moreover, a recent report showed 
that BDNF, tPA and plasmin protein are 
packaged in dense core granules and 
transported into dendrites [49]. 
 
In the SCN, plasminogen 
expression is prominent in the 
dorsomedial shell [14].  Moreover, tPA 
has been shown to localize at 
vasopressin-containing neurons, where 
high levels of plasminogen have been 
found [15, 16]. However, these studies did 
not address the critical issue of the 
cellular localization of these proteins, 
which we hypothesize to be located 
extracellularly. 
 
Our results suggest that tPA is 
expressed in SCN neurons and, 
importantly, it is present in the media.  
Secretion of tPA into the media is 
consistent with its proteolytic activities 
shown in previous studies, although these 
studies are not in the SCN. Therefore, 
these results greatly strengthen our 
hypothesis that these proteins act 
extracellularly to regulate glutamate-
induced phase shifts. 
 
In order to further confirm our 
hypothesis, we need to determine 
whether the tPA/plasmin and PAI-1 
expression patterns in the media change 
over 24 hours. Our data from FSK-
synchronized cells appear to indicate 
there are higher levels of tPA in the media 
during mid-subjective day (CT3-9). 
Unfortunately, these data are not 
conclusive because the samples must be 
normalized to actin to confirm equal 
amounts of protein were loaded in each 
lane. We are now focusing our work on 
trouble-shooting the actin immunoblots. 
 
Another concern is that the tPA 
antibody reacted with the PAI-1 positive 
controls. This cross-reactivity could be 
due to a problem that occurred during the 
antibody production. In addition, in 
Figure 4, rather than having one specific 
band in each blot, there were two 
distinctive bands. In other blots, the 
bands were not concise but rather 
expansive. This could be due to the tPA 
antibody binding non-specifically to other 
proteins. Alternatively, tPA is known to be 
cleaved into slightly smaller products, and 
so these bands could represent those 
cleavage products. In addition, different 
isoforms of tPA have been reported, and 
some of these are differentially 
glycosylated [50, 51]. 
 
Until 2006, protein precipitation of 
rat brain proteins had utilized the 
TCA/acetone procedure [52]. Classical 
TCA/acetone extraction methods have 
been determined to be very effective as a 
precipitant [53], instantly eliminating 
proteolytic and other modifying 
enzymatic activity [54].  However, a 
disadvantage of TCA precipitated protein 
is that it is difficult to redissolve, and loss 
of protein may occur [52, 55]. This may 
explain the inconsistency of the tPA bands 
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in our western blots as well as why actin 
did not show up as it was expected to.  
 
Studies concerning the localization 
and abundance of tPA, plasmin and PAI-1 
in the brain are scarce. The few studies 
that do investigate their presence in the 
brain are limited to the hippocampus, 
cerebral cortex and hypothalamus. An 
abundant and localized expression of tPA 
is observed in the bed nucleus of the stria 
terminalis (BST) in the hypothalamus; 
restraint stress and injection of 
corticotopin-releasing factor cause tPA to 
be released into the extracellular space, 
promoting neuronal activation [56]. The 
function of this release however is not 
known. 
 
Of particular interest in my studies 
is the reported interaction of tPA with the 
NMDA (N-methyl D-aspartate) receptor. 
tPA has been determined to act directly 
with the NMDA receptor via subunit 
cleavage [57] as well as indirectly via its 
effects on BDNF. It has been determined 
that when cortical neurons are 
depolarized, they release tPA that 
interacts with and cleaves the NR1 
subunit of the NMDA receptor [57]. Thus, 
tPA potentiates signaling mediated by 
glutamatergic receptors by modifying the 
properties of the NMDA receptor [57]. 
The cleavage interaction between the 
subunit and tPA can be prevented by 
addition of PAI-1 [57]. In addition, tPA 
treatment selectively potentiates the 
NMDA-induced increase in intracellular 
Ca+2 concentrations, which is pertinent to 
the activation of the NMDA receptor [57]. 
 
In the hippocampus, NMDA 
receptors play a crucial role in long term 
potentiation (LTP), which is the 
mechanism for the production of long 
term memory. tPA has profound effects 
on the late phase of LTP (L-LTP). An 
inhibitor of tPA blocks L-LTP, whereas 
extracellular application of tPA enhances 
L-LTP induced by a single tetatus, which 
by itself induces early LTP (E-LTP) [58]. 
Induction of L-LTP in turn enhances the 
expression of tPA in the hippocampus 
[59]. tPA can also be secreted from 
neuronal growth cones and axonal 
terminals [60], and neuronal membrane 
depolarization also induces secretion of 
tPA into the extracellular space in the 
hippocampus in a Ca+2 dependent manner 
[61]. The inactive zymogen, plasminogen 
(which is converted to plasmin via tPA) 
mRNA and protein in the hippocampus 
are exclusively expressed in neurons and 
primarily in the apical dendrites of 
pyramidal cells [62]. Not only do tPA 
knockout mice exhibit severe impairment 
of L-LTP, so did plasmin knockout mice 
[12]. Since it has been determined that a 
major function of the tPA/plasmin system 
is to convert proBDNF to mBDNF at 
hippocampal synapses, it has also been 
determined that such conversion is 
critical and necessary for the expression 
of L-LTP [12]. As already discussed, we 
have determined the glutamate-induced 
phase shifts require this conversion in the 
SCN as well.  
 
5.0 Conclusion 
 
We hypothesized that the 
extracellular actions of tPA/plasmin 
regulate mBDNF production which 
modulates how glutamate signaling 
affects SCN rhythmic activity. This led us 
to believe that the expression, 
localization, and activity levels of these 
proteins are regulated in the SCN. Our 
results suggest that tPA is expressed in 
SCN neurons and present in the media. 
However, we have yet to determine the 
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pattern of tPA/plasmin and PAI-1 
expression in the media due to difficulties 
in normalizing actin to the protein 
expression levels and the possibility of 
non-specific binding of the tPA antibody 
to other proteins. Future studies will 
initially focus on fine-tuning the actin 
immunoblots and then will turn to 
producing consistent protein expression 
patterns. 
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